Evidence map›Paper›PMID 39833231›Full record

ArticleScientific reports2025

Surface plasmon resonance detection of anti-cancer drug flutamide by graphitic carbon nitride/chitosan nanocomposite.

Hassan Nasiri, Karim Abbasian

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hassan NasiriFaculty of Electrical and Computer Engineering, University of Tabriz, Tabriz, Iran. h.nasiri@tabrizu.ac.ir.
Karim AbbasianFaculty of Electrical and Computer Engineering, University of Tabriz, Tabriz, Iran. k_abbasian@tabrizu.ac.ir.

Funding

University of Tabriz S/1490
6 · The paper itself

Abstract

The g-C3N4/CS biosensor was designed, fabricated, and tested using compounds such as glucose, urine, lactose, and flutamide at a molarity of 10 µM, which could demonstrate a high sensitivity of 200 μm-1 for flutamide. Powerful effective medium theory and FDTD simulation were used to predict the most favorable mode and plasmonic properties of a graphite carbon nitride and chitosan nanocomposite. The research also explores the characteristics of surface plasmon resonance exhibited by the nanocomposite as the chitosan content is adjusted. Subsequent simulations are conducted on nanocomposites incorporating a thin layer and a modified gold structure. The intricate simulations ultimately reveal the optimal combination, tested under three different pH conditions (6.2, 7.2, and 8). In acidic conditions, the kinetic profile yielded a K

Indexed as

Antineoplastic AgentsChitosanFlutamideGraphiteNanocompositesNitrogen CompoundsSurface Plasmon ResonanceBiosensing TechniquesGoldHumansHydrogen-Ion ConcentrationLimit of DetectionAntineoplastic AgentsChitosanFlutamideGoldGraphitegraphitic carbon nitrideNitrogen CompoundsFlutamide biosensorGraphitic-carbon nitrite-chitosanSPR sensor

Identifiers

PMID39833231
PMCPMC11747246

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.